Trefoil Therapeutics develops biologic treatments for diseases that affect the cornea. Access participated in the $28 million Series A that closed in July 2019.
Passage Bio is a gene therapy biotech startup founded by Dr. James Wilson, working on treating rare neurological disorders such as Krabbe disease and GM1 gangliosidosis. Access Biotechnology led the recent $110 million Series B funding.
Dicerna Pharmaceuticals has developed a proprietary therapeutic platform based on RNA interference (RNAi) technology to silence specific genes known to cause or drive a wide range of diseases. The RNAi process uses carefully selected RNA molecules to destroy the messenger RNAs (mRNAs) of harmful genes.
Boston and Jerusalem-based Gamida Cell is developing technology to improve hematopoietic stem cell transplantation and other cell therapies for cancer and hematologic disorders.
Disc Medicine is developing novel treatments for dysregulated iron metabolism. Access participated in Disc Medicine’s $50 million Series A in September 2019.